Andy Plump, Takeda R&D chief (Jeff Rumans for Endpoints News)
In its largest single-asset purchase ever, Takeda snaps up TYK2 drug for $4B upfront
Takeda is buying Nimbus’ late-stage TYK2 inhibitor, an oral drug for autoimmune diseases, for $4 billion in cash upfront. That sets Takeda up to compete …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
